Other metabolic agents (local classification)
ATC code: V03AX-CEREBROLYSIN (Cerebrolysin (local code))
The manufacturer claims neurotrophic and neuroprotective effects via low-molecular-weight peptide fractions derived from pig brain. The mechanism has not been fully substantiated in independent literature. The product is widely used in Eastern Europe and Asia but is not registered in the United States or most Western European countries.
Not recommended
The 2020 Cochrane Systematic Review on Cerebrolysin in acute ischemic stroke found no convincing evidence of reduced mortality or disability. Evidence quality was rated low due to risk of bias in manufacturer-sponsored studies and result heterogeneity. International 2019 and 2021 guidelines do not mention the drug in standard stroke management.
Not recommended
For Alzheimer disease and other dementias, Cerebrolysin is not mentioned in , , or guidelines. Evidence-based therapy consists of acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine, with modest cognitive benefit.
Use in pregnancy is not recommended due to limited data.
Cerebrolysin (porcine brain peptides) is evaluated for the following indications with varying evidence strength: Ischemic stroke (evidence tier D), Dementia (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Cerebrolysin (porcine brain peptides) (≥ 1 in 100): Allergic skin reactions, Injection site redness and pain, Dizziness, Nausea. See the Safety section for uncommon and serious reactions.
Use in pregnancy is not recommended due to limited data.
Cerebrolysin (porcine brain peptides) is contraindicated in: Allergic diathesis; Severe renal failure; Status epilepticus, grand mal seizures; Hypersensitivity. Full list in the Safety section.